Full Breakdown
Roche’s Experimental Obesity Shot Shows 15.5% Weight Loss in Mid-Stage Trial
By Drooid · · How we work
Core Trial Results
In a mid-stage study of 447 patients with type-2 diabetes who were overweight or obese, Roche’s once-weekly injection enicepatide (formerly CT-388) produced a 15.5% average reduction in body weight after 48 weeks at the highest 24 mg dose. The same dose lowered HbA1c by 2.65%, and about 62% of participants achieved HbA1c levels below 5.7%, moving them into the non-diabetic range. Treatment discontinuation due to side effects occurred in roughly 2% of patients, compared with none in the placebo group, and most gastrointestinal events were mild to moderate. Roche reported no weight-loss plateau during the observation period.
Background & Market Context
The global market for weight-loss drugs is projected to reach up to $150 billion, currently dominated by Eli Lilly’s Zepbound and Novo Nordisk’s offerings. Roche aims to compete with a GLP-1/GIP dual-agonist that mirrors the mechanism of Zepbound. The drug was originally developed by Carmot Therapeutics, which Roche acquired for $3.1 billion in 2023. Competitors also include AstraZeneca and Amgen, all seeking entry into the rapidly expanding obesity-treatment space.
Official Statements & Responses
Roche said the mid-stage data “look competitive” against rival Phase 3 results and highlighted a 2% discontinuation rate versus higher rates reported for Eli Lilly’s Mounjaro in comparable studies. At its July half-year media conference, pharmaceuticals chief Teresa Graham indicated the company will develop enicepatide both as a standalone therapy and in combination for patients needing greater weight loss or tighter glycemic control. Goldman Sachs analyst James Quigley cautioned that detailed placebo-adjusted results and Phase 3 replication are needed to confirm the benefit. Vontobel analyst Stefan Schneider described the profile as “competitive,” noting the combination of normalized glucose and sustained weight loss, and projected a possible launch as early as 2028 with peak sales of CHF 2 billion. Roche shares slipped 0.6% in early Zurich trading following the announcement.
Future Plans & Impact
Roche already has two late-stage obesity trials in progress and plans to initiate late-stage glycemic-control and cardiovascular-outcome studies in the first half of 2027. The company also intends to test higher doses of enicepatide and explore combination regimens with other weight-loss agents. If Phase 3 results confirm the mid-stage findings, enicepatide could broaden treatment options for patients with diabetes-related obesity and reshape market dynamics in a sector poised for multi-billion-dollar growth.